南非妇女每年一次替诺福韦阿拉芬胺硅胶皮下植入物的安全性、耐受性和药代动力学：一项两部分、随机、安慰剂对照、双盲、首次人体一期试验

IF 13 1区医学 Q1 IMMUNOLOGY

Lancet Hiv Pub Date : 2025-06-27 DOI:10.1016/s2352-3018(25)00079-7

Tanuja N Gengiah PhD, Lara Lewis MS, Ishana Harkoo MBChB, Leila E Mansoor PhD, Johara Khan MBChB, Zainab Kharva MBChB, Razia Hassan-Moosa MBChB, Natasha Samsunder PhD, Prof Catherine Hankins PhD, Prof Bruno Pozzetto PhD, James F Rooney MD, Jaideep Gogtay MBBS, John A Moss PhD, Marc M Baum PhD, Prof Salim S Abdool Karim PhD, Prof Quarraisha Abdool Karim PhD

{"title":"南非妇女每年一次替诺福韦阿拉芬胺硅胶皮下植入物的安全性、耐受性和药代动力学：一项两部分、随机、安慰剂对照、双盲、首次人体一期试验","authors":"Tanuja N Gengiah PhD, Lara Lewis MS, Ishana Harkoo MBChB, Leila E Mansoor PhD, Johara Khan MBChB, Zainab Kharva MBChB, Razia Hassan-Moosa MBChB, Natasha Samsunder PhD, Prof Catherine Hankins PhD, Prof Bruno Pozzetto PhD, James F Rooney MD, Jaideep Gogtay MBBS, John A Moss PhD, Marc M Baum PhD, Prof Salim S Abdool Karim PhD, Prof Quarraisha Abdool Karim PhD","doi":"10.1016/s2352-3018(25)00079-7","DOIUrl":null,"url":null,"abstract":"Women in sub-Saharan Africa are at high risk for HIV acquisition. To overcome adherence challenges with daily oral pre-exposure prophylaxis we developed and tested the safety, tolerability, and pharmacokinetics of a novel long-acting tenofovir alafenamide implant.","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"46 1","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-human, phase 1 trial\",\"authors\":\"Tanuja N Gengiah PhD, Lara Lewis MS, Ishana Harkoo MBChB, Leila E Mansoor PhD, Johara Khan MBChB, Zainab Kharva MBChB, Razia Hassan-Moosa MBChB, Natasha Samsunder PhD, Prof Catherine Hankins PhD, Prof Bruno Pozzetto PhD, James F Rooney MD, Jaideep Gogtay MBBS, John A Moss PhD, Marc M Baum PhD, Prof Salim S Abdool Karim PhD, Prof Quarraisha Abdool Karim PhD\",\"doi\":\"10.1016/s2352-3018(25)00079-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Women in sub-Saharan Africa are at high risk for HIV acquisition. To overcome adherence challenges with daily oral pre-exposure prophylaxis we developed and tested the safety, tolerability, and pharmacokinetics of a novel long-acting tenofovir alafenamide implant.\",\"PeriodicalId\":48725,\"journal\":{\"name\":\"Lancet Hiv\",\"volume\":\"46 1\",\"pages\":\"\"},\"PeriodicalIF\":13.0000,\"publicationDate\":\"2025-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Hiv\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s2352-3018(25)00079-7\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Hiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2352-3018(25)00079-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

撒哈拉以南非洲地区的妇女感染艾滋病毒的风险很高。为了克服每日口服暴露前预防的依从性挑战，我们开发并测试了一种新型长效替诺福韦阿拉芬胺植入物的安全性、耐受性和药代动力学。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-human, phase 1 trial

Women in sub-Saharan Africa are at high risk for HIV acquisition. To overcome adherence challenges with daily oral pre-exposure prophylaxis we developed and tested the safety, tolerability, and pharmacokinetics of a novel long-acting tenofovir alafenamide implant.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lancet Hiv IMMUNOLOGYINFECTIOUS DISEASES&-INFECTIOUS DISEASES

CiteScore

19.90

自引率

4.30%

发文量

368

期刊介绍： The Lancet HIV is an internationally trusted source of clinical, public health, and global health knowledge with an Impact Factor of 16.1. It is dedicated to publishing original research, evidence-based reviews, and insightful features that advocate for change in or illuminates HIV clinical practice. The journal aims to provide a holistic view of the pandemic, covering clinical, epidemiological, and operational disciplines. It publishes content on innovative treatments and the biological research behind them, novel methods of service delivery, and new approaches to confronting HIV/AIDS worldwide. The Lancet HIV publishes various types of content including articles, reviews, comments, correspondences, and viewpoints. It also publishes series that aim to shape and drive positive change in clinical practice and health policy in areas of need in HIV. The journal is indexed by several abstracting and indexing services, including Crossref, Embase, Essential Science Indicators, MEDLINE, PubMed, SCIE and Scopus.